Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Jefferies Financial Group lifted their FY2022 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Tuesday, November 6th. Jefferies Financial Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings of $2.42 per share for the year, up from their previous estimate of $2.29.
Several other analysts also recently issued reports on the company. Morgan Stanley restated an “equal weight” rating and issued a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 10th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 29th. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Wednesday, October 3rd. Robert W. Baird restated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 3rd. Finally, Barclays restated an “overweight” rating and issued a $92.00 price objective (up from $74.00) on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $75.95.
Shares of NASDAQ:RARE opened at $52.24 on Thursday. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $90.98. The firm has a market capitalization of $2.71 billion, a PE ratio of -6.97 and a beta of 2.34.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The business had revenue of $11.80 million for the quarter, compared to the consensus estimate of $11.97 million. During the same period in the prior year, the business earned ($1.87) earnings per share. The business’s revenue was up 5800.0% on a year-over-year basis.
In related news, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total value of $603,469.00. Following the completion of the transaction, the chief financial officer now directly owns 56,828 shares in the company, valued at $5,118,497.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Aliski sold 6,000 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $55.67, for a total value of $334,020.00. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at $4,042,198.70. The disclosure for this sale can be found here. Insiders sold 37,250 shares of company stock valued at $2,747,319 over the last quarter. Insiders own 8.40% of the company’s stock.
Large investors have recently made changes to their positions in the business. Advisors Asset Management Inc. acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $181,000. Janney Montgomery Scott LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $313,000. Xact Kapitalforvaltning AB increased its stake in Ultragenyx Pharmaceutical by 49.7% during the first quarter. Xact Kapitalforvaltning AB now owns 6,623 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 2,200 shares during the last quarter. JBF Capital Inc. acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $384,000. Finally, Strs Ohio increased its stake in Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 4,300 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.